Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice paper.
Hughes, Daniel Yong, Kwee Ramasamy, Karthik Stern, Simon Boyle, Eileen Ashcroft, John Basheer, Faisal Rabin, Neil Pratt, Guy Pratt, Guy
Hughes, Daniel
Yong, Kwee
Ramasamy, Karthik
Stern, Simon
Boyle, Eileen
Ashcroft, John
Basheer, Faisal
Rabin, Neil
Pratt, Guy
Pratt, Guy
Abstract
Multiple myeloma is a bone marrow-based plasma cell tumour that develops from asymptomatic pre-cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high-risk disease may be available. Restaging is required if evidence for progression.
MIDER Authors
Citations
Altmetric:
Date
2024-02-23
Type
Article
Subject
Haematology, Oncology. Pathology.
Collections
Citation
Hughes D, Yong K, Ramasamy K, Stern S, Boyle E, Ashcroft J, Basheer F, Rabin N, Pratt G. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. Br J Haematol. 2024 Apr;204(4):1193-1206. doi: 10.1111/bjh.19333. Epub 2024 Feb 23.
Journal / Source Title
British Journal of Haematology
DOI
10.1111/bjh.19333
PMID
38393718
Publisher
Wiley
Publisher’s URL
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2141